Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.2% - What's Next?

Key Points

• Shares of Enliven Therapeutics (ELVN) fell 4.2% to about $43.40 on Monday (intraday low $42.94) on light volume (~395,620 shares, ~70% below the average), while the stock remains above its 50‑ and 200‑day moving averages.
• Analyst views are mixed but generally positive: five Buys vs. one Sell yield a consensus "Moderate Buy" and an average target of $43.40, with HC Wainwright and Mizuho recently raising targets to $56 and $45, respectively.
• Company fundamentals and insider activity present caution — Enliven missed quarterly EPS estimates (‑$0.48 vs. ‑$0.42 expected) and insiders have sold roughly 37,460 shares (~$1.04M) in the past 90 days.

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) traded down 4.2% during trading on Monday . The stock traded as low as $42.94 and last traded at $43.4030. 395,620 shares changed hands during mid-day trading, a decline of 70% from the average session volume of 1,311,940 shares. The stock had previously closed at $45.32.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ELVN. HC Wainwright lifted their price target on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the company a "buy" rating in a report on Thursday, March 26th. Wall Street Zen lowered shares of Enliven Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, February 28th. Mizuho lifted their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the company an "outperform" rating in a report on Wednesday, March 25th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enliven Therapeutics in a report on Wednesday, January 21st. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $43.40.

Enliven Therapeutics Stock Performance

The company has a market capitalization of $2.64 billion, a P/E ratio of -23.78 and a beta of 0.26. The firm's fifty day moving average is $31.44 and its 200-day moving average is $24.53.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.06). As a group, analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Insiders Place Their Bets

In other Enliven Therapeutics news, Director Richard A. Heyman sold 1,230 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total transaction of $32,201.40. Following the sale, the director directly owned 22,647 shares of the company's stock, valued at $592,898.46. The trade was a 5.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Benjamin Hohl sold 10,000 shares of the business's stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $29.58, for a total transaction of $295,800.00. Following the sale, the chief financial officer directly owned 51,000 shares in the company, valued at $1,508,580. The trade was a 16.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 37,460 shares of company stock valued at $1,041,104 in the last ninety days. 25.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ELVN. Candriam S.C.A. lifted its position in shares of Enliven Therapeutics by 46.3% in the 3rd quarter. Candriam S.C.A. now owns 609,352 shares of the company's stock worth $12,473,000 after purchasing an additional 192,702 shares during the period. HighVista Strategies LLC lifted its position in shares of Enliven Therapeutics by 83.1% in the 3rd quarter. HighVista Strategies LLC now owns 259,135 shares of the company's stock worth $5,304,000 after purchasing an additional 117,619 shares during the period. Tudor Investment Corp ET AL acquired a new position in shares of Enliven Therapeutics in the 3rd quarter worth approximately $334,000. Tower Research Capital LLC TRC lifted its position in shares of Enliven Therapeutics by 194.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company's stock worth $106,000 after purchasing an additional 3,490 shares during the period. Finally, BNP Paribas Financial Markets lifted its position in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock worth $75,000 after purchasing an additional 930 shares during the period. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.